Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.
about
Treatment with rituximab in benign and malignant hematologic disorders in children.Herpesvirus infections in organ transplant recipientsPrevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants.Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment.T cell-based therapies for EBV-associated malignancies.Hodgkin's lymphoma, Epstein-Barr virus reactivation and fatal haemophagocytic syndrome.Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.Immunotherapy for Epstein-Barr virus-associated tumors.Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review.EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning.Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in ChildhoodDiagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.Immunotherapy for epstein-barr virus-related lymphomas.T-cell therapies for Epstein-Barr virus-associated lymphomas.Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma.Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the EuropeHigh incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants.Treatment of PTLD with rituximab or chemotherapy.Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma.Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease.Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation.Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single instituteLow mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin
P2860
Q33374660-B89E9A8E-0842-4261-9D75-DB93AEB19A4EQ34579836-48B84D5E-4EF0-4D2B-BB89-92A419B43D1FQ35001143-67C4FCE6-4FD0-41AC-B160-948DEB7BA075Q35296850-92704166-79F9-44A8-BF62-E6D19E7ADA0AQ35609768-C1068A62-22D1-4429-9AB8-635A22A3D21DQ35640337-1612CB54-44BC-4A23-9FD9-78D8A4CE23CBQ35686137-AC9DE568-F6E5-4637-A30D-E6B3D35649EFQ35888698-8A58E91B-18A0-4781-977B-44AE538AD68CQ36307574-CA70153B-8A13-416D-982F-45196B0A1CF8Q36435819-1E5982AB-461F-4AB1-BBA9-08154063E09CQ36684513-6B604393-7842-40E3-BBD4-E7CD145F1F1AQ36746437-E42DC917-8164-4F78-970F-B117E65A1B1CQ37012569-B8D42DD1-DCCE-4339-9515-A6926385D789Q37055896-C27D3A11-C5EF-4830-A21C-1C08E387A816Q37426542-641A1788-A2CE-4711-803E-B41BD23254EBQ37807871-66DD4378-C707-40B5-90AF-D26F8E3BE56EQ37854471-94C1A869-A78F-4CBB-A9DC-438E746C9A5FQ37948940-F67ADF1C-FF14-4EEF-BFFF-51B877061B54Q40302748-7FC260FE-C482-48B1-B59C-00A3229ABD3AQ40455103-C0493502-F1F4-453B-8C6F-77167A24CBC9Q40511369-6D9CAC6A-9E23-4862-BD4C-2F550017944DQ42258745-67E420BC-EC74-426A-8E64-05430354C53FQ43775527-1EFE8E88-3C7E-4722-A782-28BC47635DA6Q44118692-F253E822-F8BC-4073-BE77-143C4D2B0CB0Q45125924-EB8D89A0-B5C6-41B9-B133-8E46238FCF9EQ45167835-C8AF03E0-28A8-493E-A8AE-669C13AF19B2Q45351139-B99A78D7-387D-4684-9592-578C108C5CC8Q45363416-2F65E0C6-92E5-4816-AC55-3122F55C155FQ45366674-708FF040-F9C5-46F8-990D-69A589472E8BQ45368771-5BF8DDA8-B576-4444-84A4-AF74F682508CQ45698505-A891E737-AB6B-433A-A5C5-E05D940ED067Q45706968-DB55CBEB-D9BC-4680-B7D1-E23C8C5EC395Q45764128-E84B6674-91F9-41D6-9E5B-B3B4A2DDA8AEQ47587300-8F2FDACD-6A2A-4449-ACC9-90DDB259248FQ57700794-425C99AB-FF3D-4F74-A26D-ADC0E7D2AA71Q58618269-CADD5AB4-8378-43A9-87A9-9B9AC2E2E301
P2860
Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Chimaeric anti-CD20 monoclonal ...... l transplantation in children.
@en
type
label
Chimaeric anti-CD20 monoclonal ...... l transplantation in children.
@en
prefLabel
Chimaeric anti-CD20 monoclonal ...... l transplantation in children.
@en
P2093
P2860
P1476
Chimaeric anti-CD20 monoclonal ...... ll transplantation in children
@en
P2093
A Matthieu-Boué
A S Carret
M Peuchmaur
Y Reguerre
P2860
P304
P356
10.1046/J.1365-2141.2001.03041.X
P407
P577
2001-10-01T00:00:00Z